﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2024v5.2">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2025-11-12T09:10:56-06:00</ReturnTs>
    <TaxPeriodEndDt>2024-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>042571780</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>AAFCPAS INC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>50 WASHINGTON STREET</AddressLine1Txt>
        <CityNm>WESTBOROUGH</CityNm>
        <StateAbbreviationCd>MA</StateAbbreviationCd>
        <ZIPCd>01581</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2024-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>043507847</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>CHARLES H HOOD FOUNDATION</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>CHAR</BusinessNameControlTxt>
      <PhoneNum>6172792230</PhoneNum>
      <USAddress>
        <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
        <CityNm>MANCHESTERBYTHESEA</CityNm>
        <StateAbbreviationCd>MA</StateAbbreviationCd>
        <ZIPCd>01944</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>NEIL SMILEY</PersonNm>
      <PersonTitleTxt>PRESIDENT AND TREASURER</PersonTitleTxt>
      <PhoneNum>6172792230</PhoneNum>
      <SignatureDt>2025-11-11</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>1</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>JOYCE RIPIANZI CPA</PreparerPersonNm>
      <PTIN>P00548581</PTIN>
      <PhoneNum>5083669100</PhoneNum>
      <PreparationDt>2025-11-11</PreparationDt>
    </PreparerPersonGrp>
    <TaxYr>2024</TaxYr>
    <BuildTS>2025-03-06 01:10:19Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="15">
    <IRS990PF documentId="RetDoc1235000001">
      <AddressChangeInd>X</AddressChangeInd>
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>101037612</FMVAssetsEOYAmt>
      <MethodOfAccountingCashInd>X</MethodOfAccountingCashInd>
      <AnalysisOfRevenueAndExpenses>
        <ContriRcvdRevAndExpnssAmt>21668457</ContriRcvdRevAndExpnssAmt>
        <DividendsRevAndExpnssAmt>2066610</DividendsRevAndExpnssAmt>
        <DividendsNetInvstIncmAmt>2003473</DividendsNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>4246783</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>15346535</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>4246783</CapGainNetIncmNetInvstIncmAmt>
        <IncmModificationsAdjNetIncmAmt>26256</IncmModificationsAdjNetIncmAmt>
        <OtherIncomeRevAndExpnssAmt referenceDocumentId="RetDoc2001500001">208682</OtherIncomeRevAndExpnssAmt>
        <OtherIncomeNetInvstIncmAmt>181544</OtherIncomeNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>28190532</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>6431800</TotalNetInvstIncmAmt>
        <TotalAdjNetIncmAmt>26256</TotalAdjNetIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>0</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>0</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>0</CompOfcrDirTrstDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">20204</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>0</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>20204</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">29863</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>0</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>29863</AccountingFeesChrtblPrpsAmt>
        <OtherProfFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002300001">116380</OtherProfFeesRevAndExpnssAmt>
        <OtherProfFeesNetInvstIncmAmt>97565</OtherProfFeesNetInvstIncmAmt>
        <OtherProfFeesDsbrsChrtblAmt>18815</OtherProfFeesDsbrsChrtblAmt>
        <TaxesRevAndExpnssAmt referenceDocumentId="RetDoc2002500001">146252</TaxesRevAndExpnssAmt>
        <TaxesNetInvstIncmAmt>40752</TaxesNetInvstIncmAmt>
        <TaxesDsbrsChrtblAmt>500</TaxesDsbrsChrtblAmt>
        <TravConfMeetingRevAndExpnssAmt>16265</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>0</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>16265</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">360097</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>0</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>360097</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>689061</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>138317</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>445744</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>2470000</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>2470000</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>3159061</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>138317</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>2915744</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>25031471</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>6293483</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>26256</AdjustedNetIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <SavAndTempCashInvstBOYAmt>204648</SavAndTempCashInvstBOYAmt>
        <SavAndTempCashInvstEOYAmt>7779857</SavAndTempCashInvstEOYAmt>
        <SavAndTempCashInvstEOYFMVAmt>7779857</SavAndTempCashInvstEOYFMVAmt>
        <CorporateStockBOYAmt>35440583</CorporateStockBOYAmt>
        <CorporateStockEOYAmt referenceDocumentId="RetDoc2018900001">47342703</CorporateStockEOYAmt>
        <CorporateStockEOYFMVAmt>47342703</CorporateStockEOYFMVAmt>
        <CorporateBondsBOYAmt>13614650</CorporateBondsBOYAmt>
        <CorporateBondsEOYAmt referenceDocumentId="RetDoc2044400001">17658588</CorporateBondsEOYAmt>
        <CorporateBondsEOYFMVAmt>17658588</CorporateBondsEOYFMVAmt>
        <OtherInvestmentsBOYAmt>18742212</OtherInvestmentsBOYAmt>
        <OtherInvestmentsEOYAmt referenceDocumentId="RetDoc2018100001">23677157</OtherInvestmentsEOYAmt>
        <OtherInvestmentsEOYFMVAmt>23677157</OtherInvestmentsEOYFMVAmt>
        <OtherAssetsBOYAmt referenceDocumentId="RetDoc2046600001">4006057</OtherAssetsBOYAmt>
        <OtherAssetsEOYAmt referenceDocumentId="RetDoc2046600001">4579307</OtherAssetsEOYAmt>
        <OtherAssetsEOYFMVAmt referenceDocumentId="RetDoc2046600001">4579307</OtherAssetsEOYFMVAmt>
        <TotalAssetsBOYAmt>72008150</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>101037612</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>101037612</TotalAssetsEOYFMVAmt>
        <TotalLiabilitiesBOYAmt>0</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>0</TotalLiabilitiesEOYAmt>
        <OrgDoesNotFollowFASB117Ind>X</OrgDoesNotFollowFASB117Ind>
        <CapitalStockBOYAmt>59300755</CapitalStockBOYAmt>
        <CapitalStockEOYAmt>59300755</CapitalStockEOYAmt>
        <AdditionalPaidInCapitalBOYAmt>0</AdditionalPaidInCapitalBOYAmt>
        <AdditionalPaidInCapitalEOYAmt>0</AdditionalPaidInCapitalEOYAmt>
        <RetainedEarningBOYAmt>12707395</RetainedEarningBOYAmt>
        <RetainedEarningEOYAmt>41736857</RetainedEarningEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>72008150</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>101037612</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>72008150</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>101037612</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>72008150</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>25031471</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt referenceDocumentId="RetDoc2049700001">3997991</OtherIncreasesAmt>
        <SubtotalAmt>101037612</SubtotalAmt>
        <OtherDecreasesAmt>0</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>101037612</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PUBLICLY TRADED SECURITIES</PropertyDesc>
          <GrossSalesPriceAmt>15202459</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11099752</CostOrOtherBasisAmt>
          <GainOrLossAmt>4102707</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4102707</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CAPITAL GAINS DIVIDENDS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>144076</GrossSalesPriceAmt>
          <GainOrLossAmt>144076</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>144076</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>4246783</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>87479</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>87479</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>87479</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>106335</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>0</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>106335</TotalPaymentsAndCreditsAmt>
        <Form2220AttachedInd referenceDocumentId="RetDoc1192000001">X</Form2220AttachedInd>
        <EsPenaltyAmt>0</EsPenaltyAmt>
        <OverpaymentAmt>18856</OverpaymentAmt>
        <AppliedToESTaxAmt>18856</AppliedToESTaxAmt>
        <RefundAmt>0</RefundAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>MA</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd>0</NewSubstantialContributorsInd>
        <OwnControlledEntityInd>1</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>HTTPS://HRIA.ORG/TMF/HOOD/</WebsiteAddressTxt>
        <IndividualWithBooksNm>AAFCPAS INC</IndividualWithBooksNm>
        <PhoneNum>5083669100</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>50 WASHINGTON STREET</AddressLine1Txt>
          <CityNm>WESTBOROUGH</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01581</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>0</ForeignAccountsQuestionInd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>0</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>0</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>1</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>1</BusinessHoldingsInd>
        <ExcessBusinessHoldingsInd>0</ExcessBusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>1</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <TransactionsFailToQlfyAsExcInd>0</TransactionsFailToQlfyAsExcInd>
        <MaintainedExpenditureRspnsInd referenceDocumentId="RetDoc2118100002">1</MaintainedExpenditureRspnsInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>NEIL SMILEY</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>PRESIDENT AND TREASURER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>JOHN O PARKER JR</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>VICE PRESIDENT AND CLERK</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ROBERT C BOUTWELL</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>BARBARA BULA</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>BRENDON BULA</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ELIZABETH HOOD</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>CLAY SMILEY</PersonNm>
          <USAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompOfHghstPdEmplOrNONETxt>NONE</CompOfHghstPdEmplOrNONETxt>
        <OtherEmployeePaidOver50kCnt>0</OtherEmployeePaidOver50kCnt>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HEALTH RESOURCES IN ACTION</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>ADMINISTRATIVE FEES</ServiceTypeTxt>
          <CompensationAmt>244367</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>PRIME BUCHHOLZ</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>273 CORPORATE DRIVE SUITE 250</AddressLine1Txt>
            <CityNm>PORTSMOUTH</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03801</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT ADVISORY SERVICES</ServiceTypeTxt>
          <CompensationAmt>78750</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <ContractorPaidOver50kCnt>0</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SumOfProgramRelatedInvstGrp>
        <Description1Txt>NEOPENDA, PBC - CHICAGO, ILCONVERTIBLE PROMISSORY NOTE</Description1Txt>
        <Expenses1Amt>200000</Expenses1Amt>
        <Description2Txt>MOTHER'S MILK IS BEST, INC. - TYNGSBORO, MACONVERTIBLE PROMISSORY NOTE</Description2Txt>
        <Expenses2Amt>200000</Expenses2Amt>
        <AllOtherProgramRltdInvstTotAmt referenceDocumentId="RetDoc2063500001">149995</AllOtherProgramRltdInvstTotAmt>
        <TotalAmt>549995</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>68770835</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>8558925</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>17615779</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>94945539</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>94945539</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>1424183</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>93521356</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>4676068</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>4676068</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>87479</TaxBasedOnInvestmentIncomeAmt>
        <TotalTaxAmt>87479</TotalTaxAmt>
        <DistributableBeforeAdjAmt>4588589</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>26256</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>4614845</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>4614845</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>2915744</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>549995</ProgramRelatedInvstTotalAmt>
        <QualifyingDistributionsAmt>3465739</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>4614845</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>3268164</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <TotalExcessDistributionCyovAmt>0</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>3465739</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>3268164</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>197575</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>0</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>0</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>4417270</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>0</ExcessDistriCyovToNextYrAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <ApplicationSubmissionInfoGrp>
          <RecipientPersonNm>CHARLENE MANCUSI DIRECTOR HRIA</RecipientPersonNm>
          <RecipientUSAddress>
            <AddressLine1Txt>29 OLD NECK ROAD</AddressLine1Txt>
            <CityNm>MANCHESTERBYTHESEA</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01944</ZIPCd>
          </RecipientUSAddress>
          <RecipientPhoneNum>6176959439</RecipientPhoneNum>
          <RecipientEmailAddressTxt>CMANCUSI@HRIA.ORG</RecipientEmailAddressTxt>
          <FormAndInfoAndMaterialsTxt>APPLICATION FORMS AVAILABLE AT WWW.TMFGRANTS.ORG/HOOD</FormAndInfoAndMaterialsTxt>
          <SubmissionDeadlinesTxt>ANNUALLY MARCH AND OCTOBER</SubmissionDeadlinesTxt>
          <RestrictionsOnAwardsTxt>RESTRICTED TO PEDIATRIC RESEARCH</RestrictionsOnAwardsTxt>
        </ApplicationSubmissionInfoGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208239</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - SUPPORTING REFUGEE MENTAL HEALTH THROUGH TRANSLATION OF EVALUATIVE INSTRUMENTS AND THROUGH A PREVENTIVE MENTAL HEALTH INTERVENTION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BANK OF AMERICA NA PO BOX 414876</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414876</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - TACKLING PULMONARY HYPOPLASIA WITH GENETIC, EPIGENETIC AND STEM CELL APPROACHES.</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>BANK OF AMERICA 222 BROADWAY ST</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - IMPROVING CHILDHOOD TUBERCULOSIS TREATMENT OUTCOMES AND POST-TB LUNG FUNCTIONING AND QUALITY OF LIFE IN RURAL SOUTH AFRICA</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - IDENTIFYING EEG-BASED BIOMARKERS OF LANGUAGE GROWTH IN PRESCHOOL-AGED CHILDREN WITH DOWN SYNDROME</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - CHARACTERIZING THE ROLE OF TWO SUBCORTICAL NUCLEI IN PREFRONTAL REGULATION OF ATTENTION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - POSTNATAL EXPOSURE TO HYPEROXIA CAUSES MALADAPTATION OF THE PREMATURE INTESTINE</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - ROLE OF XENOBIOTIC PATHWAYS TO MODULATE INTESTINAL EPITHELIAL METABOLISM, AS POSSIBLE TARGETS FOR OBESITY AND DIABETES</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE OF MESENCHYMAL STEM CELLS TO ENHANCE IMMUNE FUNCTION IN A MODEL OF NEONATAL INFECTION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH-HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>RESEARCH OPERATIONS 1 MEDICAL</AddressLine1Txt>
            <AddressLine2Txt>CENTER DRIVE</AddressLine2Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - EVALUATING MECHANISMS OF ENVIRONMENTAL CHEMICAL EXPOSURE WITH DEVELOPING ZEBRAFISH URINARY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>70000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS EYE AND EAR INFIRMARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - ADVANCING THE RETINOIC ACID SIGNALING ACTIVATOR AS A NOVEL THERAPEUTIC IN MOUSE MODELS OF RETINAL DEGENERATION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DECIPHERING THE MECHANISM UNDERLYING SHORT- AND LONG-TERM AIRWAY HYPERRESPONSIVENESS FOLLOWING EARLY-LIFE RSV INFECTION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - EVALUATING EFFECTIVE COMBINATIONS OF MODIFIABLE FACTORS FOR PREVENTING YOUTH DEPRESSION RISK</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - TARGETING LIPID DYSREGULATION IN HEREDITARY SPASTIC PARAPLEGIA</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208239</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - IMPACT OF EARLY LIFE IMMUNE CHALLENGES ON BRAIN WIRING</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS EYE AND EAR INFIRMARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - CHARACTERIZATION OF SENSORINEURAL HEARING LOSS IN NEUROFIBROMATOSIS TYPE 2</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - NANOBODY-BASED IMMUNOTHERAPY FOR MODULATING INFLAMMATION IN JUVENILE IDIOPATHIC ARTHRITIS</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DANA-FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - TARGETING CHROMATIN REGULATORS IN NUP98-REARRANGED ACUTE MYELOID LEUKEMIA</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD PILGRIM HEALTH CARE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - SOCIOECONOMIC INEQUITIES IN RSV IMMUNIZATION AND POPULATION-BASED OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - UNDERSTANDING MECHANISMS FOR IMPROVED PEDIATRIC SKELETAL HEALTH: NOVEL REGULATORS OF CHONDROCYTE-TO-OSTEOBLAST TRANSDIFFERENTIATION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O JPMORGAN CHASE 270 PARK AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - HISTONE MARKS PROFILING: DECODING CELLULAR MECHANISMS IN CONGENITAL RARE DISORDERS CAUSED BY PATHOGENIC VARIANTS IN CHROMATIN-MODIFIER GENES</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - EPIGENETIC REGULATION OF NEURAL EXCITABILITY IN A MOUSE MODEL OF INFANTILE EPILEPSY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOD PEDIATRIC INNOVATION HUB</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>2470000</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - EVALUATING EFFECTIVE COMBINATIONS OF MODIFIABLE FACTORS FOR PREVENTING YOUTH DEPRESSION RISK</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - TARGETING LIPID DYSREGULATION IN HEREDITARY SPASTIC PARAPLEGIA</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208239</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - IMPACT OF EARLY LIFE IMMUNE CHALLENGES ON BRAIN WIRING</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS EYE AND EAR INFIRMARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - CHARACTERIZATION OF SENSORINEURAL HEARING LOSS IN NEUROFIBROMATOSIS TYPE 2</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - NANOBODY-BASED IMMUNOTHERAPY FOR MODULATING INFLAMMATION IN JUVENILE IDIOPATHIC ARTHRITIS</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DANA-FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - TARGETING CHROMATIN REGULATORS IN NUP98-REARRANGED ACUTE MYELOID LEUKEMIA</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD PILGRIM HEALTH CARE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - SOCIOECONOMIC INEQUITIES IN RSV IMMUNIZATION AND POPULATION-BASED OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - UNDERSTANDING MECHANISMS FOR IMPROVED PEDIATRIC SKELETAL HEALTH: NOVEL REGULATORS OF CHONDROCYTE-TO-OSTEOBLAST TRANSDIFFERENTIATION</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O JPMORGAN CHASE 270 PARK AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - HISTONE MARKS PROFILING: DECODING CELLULAR MECHANISMS IN CONGENITAL RARE DISORDERS CAUSED BY PATHOGENIC VARIANTS IN CHROMATIN-MODIFIER GENES</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - EPIGENETIC REGULATION OF NEURAL EXCITABILITY IN A MOUSE MODEL OF INFANTILE EPILEPSY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOD PEDIATRIC INNOVATION HUB</GrantOrContributionPurposeTxt>
          <Amt>4600000</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>5600000</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <DividendsAndInterestFromSecDtl>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>2066610</ExclusionAmt>
        </DividendsAndInterestFromSecDtl>
        <GainSalesAstOthThanInvntryGrp>
          <ExclusionCd>18</ExclusionCd>
          <ExclusionAmt>4246783</ExclusionAmt>
        </GainSalesAstOthThanInvntryGrp>
        <OtherRevenueDescribedGrp>
          <Desc>INCOME FROM ALTERNATIVE INVESTMENTS</Desc>
          <ExclusionCd>18</ExclusionCd>
          <ExclusionAmt>181544</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>RETURNED GRANTS</Desc>
          <RelatedOrExemptFunctionIncmAmt>26256</RelatedOrExemptFunctionIncmAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>OTHER INVESTMENT INCOME</Desc>
          <RelatedOrExemptFunctionIncmAmt>882</RelatedOrExemptFunctionIncmAmt>
        </OtherRevenueDescribedGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>0</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>6494937</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>27138</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>6522075</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <RlnOfActyToAccomOfExmptPrpsGrp>
        <RlnOfActyToAccomOfExmptPrpsGrp>
          <LineNumberTxt>11C</LineNumberTxt>
          <RelationshipStatementTxt>EXCESS FUNDS RETURNED FROM GRANTS PREVIOUSLY PAID OUT.</RelationshipStatementTxt>
        </RlnOfActyToAccomOfExmptPrpsGrp>
        <RlnOfActyToAccomOfExmptPrpsGrp>
          <LineNumberTxt>11D</LineNumberTxt>
          <RelationshipStatementTxt>SETTLEMENT PROCEEDS ON INVESTMENTS</RelationshipStatementTxt>
        </RlnOfActyToAccomOfExmptPrpsGrp>
      </RlnOfActyToAccomOfExmptPrpsGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>0</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <GeneralRuleInd>X</GeneralRuleInd>
      <ContributorInformationGrp>
        <ContributorNum>1</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1Txt>ESTATE OF JUDITH HOOD</BusinessNameLine1Txt>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1Txt>BANK OF AMERICA 1025 MAIN ST</AddressLine1Txt>
          <CityNm>WALTHAM</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02451</ZIPCd>
        </ContributorUSAddress>
        <TotalContributionsAmt>21668457</TotalContributionsAmt>
        <PersonContributionInd>X</PersonContributionInd>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>ACCOUNTING &amp; TAX PREPARATION FEES</CategoryTxt>
        <Amt>29863</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>29863</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <AllOthProgRltdInvestmentsSch documentId="RetDoc2063500001">
      <AllOtherProgramRelatedInvstGrp>
        <Desc>ARGUS COGNITIVE, INC. - LEBANON, NH SIMPLE AGREEMENT FOR FUTURE EQUITY</Desc>
        <Amt>49995</Amt>
      </AllOtherProgramRelatedInvstGrp>
      <AllOtherProgramRelatedInvstGrp>
        <Desc>MULBERRY THERAPEUTICS - WELLESLEY, MA CONVERTIBLE PROMISSORY NOTE</Desc>
        <Amt>100000</Amt>
      </AllOtherProgramRelatedInvstGrp>
    </AllOthProgRltdInvestmentsSch>
    <ExpenditureResponsibilityStmt documentId="RetDoc2118100002">
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALDATU BIOSCIENCES INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>C/O ARSENAL LAB SPACE 201 DEXTER</AddressLine1Txt>
          <AddressLine2Txt>AVE</AddressLine2Txt>
          <CityNm>WATERTOWN</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02472</ZIPCd>
        </USAddress>
        <GrantDt>2016-02-23</GrantDt>
        <GrantAmt>100000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF A SIMPLE, RAPID, THERMOSTABLE KIT THAT IDENTIFIES CLINICALLY ACTIONABLE HIV MUTATIONS FOUND IN PATIENTS FAILING A FIRST-LINE DRUG REGIMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>100000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/12/2024, 6/27/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ALDATU BIOSCIENCES, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ANIDA PHARMA INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>155 BROOKLINE STREET SUITE 005</AddressLine1Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02139</ZIPCd>
        </USAddress>
        <GrantDt>2020-12-21</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PRECLINICAL DEVELOPMENT OF A PREVENTATIVE TREATMENT FOR RETINOPATHY OF PREMATURITY, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/24/2024, 1/3/2025, 6/17/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-07-21</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ANIDA PHARMA, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ARGUS COGNITIVE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>DARTMOUTH REGIONAL TECHNICAL CTR 16</AddressLine1Txt>
          <AddressLine2Txt>CAVENDISH CT</AddressLine2Txt>
          <CityNm>LEBANON</CityNm>
          <StateAbbreviationCd>NH</StateAbbreviationCd>
          <ZIPCd>03766</ZIPCd>
        </USAddress>
        <GrantDt>2021-05-10</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 3/5/2024,5/18/2024, 6/6/2024, 7/3/2024, 7/26/2024, 9/9/2024, 9</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-08-23</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ARGUS COGNITIVE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>DARTMOUTH REGIONAL TECHNICAL CTR 16</AddressLine1Txt>
          <AddressLine2Txt>CAVENDISH CT</AddressLine2Txt>
          <CityNm>LEBANON</CityNm>
          <StateAbbreviationCd>NH</StateAbbreviationCd>
          <ZIPCd>03766</ZIPCd>
        </USAddress>
        <GrantDt>2023-07-10</GrantDt>
        <GrantAmt>25000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>25000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 3/5/2024,5/18/2024, 6/6/2024, 7/3/2024, 7/26/2024, 9/9/2024, 9</DatesOfReportsByGranteeTxt>
        <VerificationDt>2024-09-13</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ARGUS COGNITIVE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>DARTMOUTH REGIONAL TECHNICAL CTR 16</AddressLine1Txt>
          <AddressLine2Txt>CAVENDISH CT</AddressLine2Txt>
          <CityNm>LEBANON</CityNm>
          <StateAbbreviationCd>NH</StateAbbreviationCd>
          <ZIPCd>03766</ZIPCd>
        </USAddress>
        <GrantDt>2024-06-24</GrantDt>
        <GrantAmt>49995</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>49995</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 3/5/2024,5/18/2024, 6/6/2024, 7/3/2024, 7/26/2024, 9/9/2024, 9</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-09-04</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIOROSA TECHNOLOGIES INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>63 BAKER STREET</AddressLine1Txt>
          <CityNm>BELMONT</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02478</ZIPCd>
        </USAddress>
        <GrantDt>2020-07-15</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 1/8/2024, 9/24/2024, 9/3/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2021-07-16</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIOROSA TECHNOLOGIES INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>63 BAKER STREET</AddressLine1Txt>
          <CityNm>BELMONT</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02478</ZIPCd>
        </USAddress>
        <GrantDt>2022-11-15</GrantDt>
        <GrantAmt>100000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>100000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 1/8/2024, 9/24/2024, 9/3/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-08-14</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BREEGI SCIENTIFIC INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>120 BEDFORD ROAD</AddressLine1Txt>
          <CityNm>WOBURN</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01801</ZIPCd>
        </USAddress>
        <GrantDt>2017-06-26</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>THE FUNDS WILL BE USED TO CONDUCT A THOROUGH CLINICAL ASSESSMENT OF BSI'S NOVEL NEONATAL INTENSIVE CARE INCUBATOR "(NICI)" IN HONDURAS AND ZAMBIA AND TO AID THE COMMERCIALIZATION EFFORTS OF THIS LIFE-SAVING MEDICAL DEVICE, THEREBY LESSENING THE BURDEN OF THE GOVERNMENT AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/3/2024, 10/1/2024, 9/26/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2021-08-02</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH BREEGI SCIENTIFIC, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DECK THERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>8 HARVARD LANE</AddressLine1Txt>
          <CityNm>HASTINGS ON HUDSON</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10706</ZIPCd>
        </USAddress>
        <GrantDt>2022-10-12</GrantDt>
        <GrantAmt>200000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF SEMI-SYNTHETIC OMEGA-3 COMPOUNDS THAT BLOCK MULTIPLE CELL-DEATH PATHWAYS INDUCED BY HYPOXIC-ISCHEMIC INJURY IN NEONATES.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>200000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/26/2024, 2/4/2025, 7/4/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-05-02</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH DECK THERAPEUTICS, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INKSPACE IMAGING INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>5635 W LAS POSITAS BLVD STE 403/404</AddressLine1Txt>
          <CityNm>PLEASANTON</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94588</ZIPCd>
        </USAddress>
        <GrantDt>2022-10-20</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF FLEXIBLE, LIGHTWEIGHT, LOW COST MRI COILS DESIGNED SPECIFICALLY FOR PEDIATRIC PATIENTS, WHILE ALSO IMPROVING IMAGE RESOLUTION AND REDUCING MRI FAILURE RATES.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 8/12/2024, 7/2/2025, 9/8/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2024-08-12</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH INKSPACE IMAGING, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MESENTECH INC</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>2222 HEALTH SCIENCES RD</AddressLine1Txt>
          <CityNm>VANCOUVER</CityNm>
          <ProvinceOrStateNm>BRITISH COLUMBIA</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
          <ForeignPostalCd>V6T2B9</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2020-11-02</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE ADVANCEMENT OF SCIENCE AND PROMOTION OF HEALTH THROUGH THE PRECLINICAL RESEARCH OF ANABOLIC BONE THERAPEUTICS THAT CAN INCREASE BONE MASS TO STRENGTHEN THE SKELETON AND THE DEVELOPMENT OF A DRUG DELIVERY SYSTEM TO BE INITIALLY APPLIED TO TWO PEDIATRIC RARE DISEASES: OSTEOGENESIS IMPERFECTA AND DUCHENNE MUSCULAR DYSTROPHY.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/4/2024, 6/5/2024, 11/19/2024, 3/6/2025, 5/20/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2022-08-26</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH MESENTECH, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MOTHERS MILK IS BEST INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1510 LAKESIDE AVENUE</AddressLine1Txt>
          <CityNm>FORT COLLINS</CityNm>
          <StateAbbreviationCd>CO</StateAbbreviationCd>
          <ZIPCd>80521</ZIPCd>
        </USAddress>
        <GrantDt>2024-12-27</GrantDt>
        <GrantAmt>200000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE CONDUCTING OF SCIENTIFIC RESEARCH RELATED TO THE DEVELOPMENT OF A MEDICAL DEVICE THAT CONCENTRATES HUMAN MILK TO PROVIDE LOW VOLUME, HIGH NUTRIENT FEEDINGS PRESCRIBED FOR PRETERM INFANTS.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 4/1/2025, 5/23/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-05-23</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH MOTHERS MILK IS BEST, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MULBERRY BIOTHERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>40 WALNUT STREET SUITE 301</AddressLine1Txt>
          <CityNm>WELLESLEY</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02481</ZIPCd>
        </USAddress>
        <GrantDt>2023-12-26</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT PRECLINICAL WORK RELATING TO THE DEVELOPMENT OF A BACTERIA-MEDIATED THERAPY FOR NEUROFIBROMATOSIS TYPE 2.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>222101</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 6/11/2024, 12/16/2024, 6/19/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-06-19</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH MULBERRY BIOTHERAPEUTICS INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MULBERRY BIOTHERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>40 WALNUT STREET SUITE 301</AddressLine1Txt>
          <CityNm>WELLESLEY</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02481</ZIPCd>
        </USAddress>
        <GrantDt>2024-12-20</GrantDt>
        <GrantAmt>100000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT PRECLINICAL WORK RELATING TO THE DEVELOPMENT OF A BACTERIA-MEDIATED THERAPY FOR NEUROFIBROMATOSIS TYPE 2.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 6/11/2024, 12/16/2024, 6/19/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-06-19</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH MULBERRY BIOTHERAPEUTICS INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NEOPENDA PBC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1623 W FULTON ST</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60612</ZIPCd>
        </USAddress>
        <GrantDt>2024-11-15</GrantDt>
        <GrantAmt>200000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE CONDUCTING OF SCIENTIFIC RESEARCH IN THE PUBLIC INTEREST RELATED TO THE DEVELOPMENT OF AFFORDABLE, LIFE-SAVING MEDICAL DEVICES TAILORED FOR LOW-RESOURCE SETTINGS SUCH AS KENYA AND EAST AFRICA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>172110</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 2/7/2025, 9/8/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-09-08</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NEOPENDA, PBC MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NICOLETTE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>100 W BROADWAY SUITE 3000</AddressLine1Txt>
          <CityNm>LONG BEACH</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90802</ZIPCd>
        </USAddress>
        <GrantDt>2021-12-23</GrantDt>
        <GrantAmt>200000</GrantAmt>
        <PurposeOfGrantTxt>TO DEVELOP AND TEST A TABLET-BASED APPLICATION THAT TRANSLATES DATA PULLED FROM A BABY'S ELECTRONIC MEDICAL RECORD INTO EASILY UNDERSTOOD, SIMPLE SENTENCES COMPLEMENTED BY VISUAL AIDS, SUCH AS GRAPHS AND CHARTS, FOR THE BENEFIT OF THE PUBLIC, INCLUDING PARENTS, IN AN ATTEMPT TO CHANGE THE STANDARD OF CARE BY IMPROVING LIVES, REDUCING MEDICAL ERRORS, AND REDUCING OVERALL HEALTHCARE COSTS.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>200000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 4/10/2024, 6/17/2024, 10/15/2025, 4/16/2025, 6/16/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2024-06-17</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NICOLETTE, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NONINVASIX INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1700 THE STRAND SUITE 1200</AddressLine1Txt>
          <CityNm>GALVESTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77555</ZIPCd>
        </USAddress>
        <GrantDt>2015-12-30</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/31/2024, 1/24/2025, 7/23/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NONINVASIX INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1700 THE STRAND SUITE 1200</AddressLine1Txt>
          <CityNm>GALVESTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77555</ZIPCd>
        </USAddress>
        <GrantDt>2016-07-27</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/31/2024, 1/24/2025, 7/23/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NONINVASIX INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1700 THE STRAND SUITE 1200</AddressLine1Txt>
          <CityNm>GALVESTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77555</ZIPCd>
        </USAddress>
        <GrantDt>2017-07-27</GrantDt>
        <GrantAmt>7000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>7000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/31/2024, 1/24/2025, 7/23/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NOVONATE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>395 OYSTER POINT BLVD SUITE 501</AddressLine1Txt>
          <CityNm>SOUTH SAN FRANCISCO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94080</ZIPCd>
        </USAddress>
        <GrantDt>2022-08-03</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO BENEFIT THE PUBLIC BY DEVELOPING MEDICAL DEVICES FOR PATIENTS IN THE NEONATAL INTENSIVE CARE UNIT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 7/25/2023, 7/27/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-07-27</VerificationDt>
        <ResultsOfVerificationTxt>NOVONATE WAS ACQUIRED IN 2023 AND THE $150,000 WAS REPAID TO THE FOUNDATION. PRIOR TO THIS, THE TRUSTEES MET WITH NOVONATE, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEWED THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NURTURE GENOMICS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>CAMBRIDGE INNOVATION CTR ONE</AddressLine1Txt>
          <AddressLine2Txt>BROADWAY KENDALL SQUARE</AddressLine2Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02142</ZIPCd>
        </USAddress>
        <GrantDt>2023-12-26</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PRE-COMMERCIAL AND PILOT DEVELOPMENT OF A SCREENING AND TELEHEALTH PLATFORM TO PROVIDE GENETIC INSIGHTS THAT HELP PARENTS AND THEIR MEDICAL PROVIDERS BETTER UNDERSTAND RISKS FROM CHILDBIRTH INTO ADOLESCENCE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 6/23/2024, 7/25/2025, 8/12/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-08-12</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NURTURE GENOMICS MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PLAKOUS THERAPEUTICS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>755 HIGHLAND OAKS DR SUITE 103</AddressLine1Txt>
          <CityNm>WINSTONSALEM</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27103</ZIPCd>
        </USAddress>
        <GrantDt>2023-07-03</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PRECLINICAL DEVELOPMENT OF A BIOLOGIC TO TREAT BABIES DIAGNOSED OR AT RISK OF DEVELOPING NECROTIZING ENTEROCOLITIS (NEC).</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 2/2/2024, 6/6/2024, 5/20/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2024-02-02</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH PLAKOUS THERAPEUTICS MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PRAPELA LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2 MAIN STREET</AddressLine1Txt>
          <CityNm>BIDDEFORD</CityNm>
          <StateAbbreviationCd>ME</StateAbbreviationCd>
          <ZIPCd>04005</ZIPCd>
        </USAddress>
        <GrantDt>2018-07-02</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF THE COMPANY'S SLEEP TECHNOLOGY PRODUCTS FOR IMPROVING THE HEALTH OF INFANTS WHO COULD BENEFIT FROM WITHDRAWAL TREATMENT AND POST-WITHDRAWAL SUPPORT OF NEONATAL ABSTINENCE SYNDROME ("NAS") A CONDITION CAUSED BY THE PRENATAL USE OF OPIOIDS OR OTHER DRUGS BY PREGNANT WOMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE, LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/17/2024, 9/24/2024, 2/1/2025, 4/1/2025, 9/4/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2020-09-10</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH PRAPELA, LLC MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PRAPELA LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2 MAIN STREET</AddressLine1Txt>
          <CityNm>BIDDEFORD</CityNm>
          <StateAbbreviationCd>ME</StateAbbreviationCd>
          <ZIPCd>04005</ZIPCd>
        </USAddress>
        <GrantDt>2023-12-20</GrantDt>
        <GrantAmt>50000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF THE COMPANY'S SLEEP TECHNOLOGY PRODUCTS FOR IMPROVING THE HEALTH OF INFANTS WHO COULD BENEFIT FROM WITHDRAWAL TREATMENT AND POST-WITHDRAWAL SUPPORT OF NEONATAL ABSTINENCE SYNDROME ("NAS") A CONDITION CAUSED BY THE PRENATAL USE OF OPIOIDS OR OTHER DRUGS BY PREGNANT WOMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE, LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>42700</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/17/2024, 9/24/2024, 2/1/2025, 4/1/2025, 9/4/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-09-04</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH PRAPELA, LLC MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>SMOLTAP INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>150 CHESTNUT STREET SUITE C</AddressLine1Txt>
          <CityNm>PROVIDENCE</CityNm>
          <StateAbbreviationCd>RI</StateAbbreviationCd>
          <ZIPCd>02903</ZIPCd>
        </USAddress>
        <GrantDt>2022-07-25</GrantDt>
        <GrantAmt>99997</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO DEVELOP A NOVEL DEVICE WHICH HOLDS AN INFANT STABLE DURING THE LUMBER PUNCTURE PROCEDURE WHEN ADMINISTERING A SPINAL TAP TO DIAGNOSE MENINGITIS IN IN FEBRILE INFANTS UP TO FOUR WEEKS OLD.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>99997</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/30/2024, 9/3/2024, 4/23/2025, 5/9/2025, 5/28/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-05-30</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH SMOLTAP, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>SMOLTAP INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>150 CHESTNUT STREET SUITE C</AddressLine1Txt>
          <CityNm>PROVIDENCE</CityNm>
          <StateAbbreviationCd>RI</StateAbbreviationCd>
          <ZIPCd>02903</ZIPCd>
        </USAddress>
        <GrantDt>2023-09-11</GrantDt>
        <GrantAmt>100000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO DEVELOP A NOVEL DEVICE WHICH HOLDS AN INFANT STABLE DURING THE LUMBER PUNCTURE PROCEDURE WHEN ADMINISTERING A SPINAL TAP TO DIAGNOSE MENINGITIS IN IN FEBRILE INFANTS UP TO FOUR WEEKS OLD.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>100000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/30/2024, 9/3/2024, 4/23/2025, 5/9/2025, 5/28/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2025-05-28</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH SMOLTAP, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>STINGRAY THERAPEUTICS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2450 HOLCOMBE BLVD SUITE X</AddressLine1Txt>
          <CityNm>HOUSTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77021</ZIPCd>
        </USAddress>
        <GrantDt>2019-04-08</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>FUNDS WILL BE USED FOR PRECLINICAL WORK FOCUSED ON PEDIATRIC BRAIN CANCERS, INCLUDING WORK TO DEVELOP PRECLINICAL MODELS AND TO TEST COMPOUNDS AGAINST MEDULLOBLASTOMA, AN ULTRA-RARE PEDIATRIC BRAIN CANCER, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 3/6/2024, 4/11/2024, 6/12/2024, 1/5/2025, 6/26/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2021-05-18</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH STINGRAY THERAPEUTICS MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THINKMD INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>166 MAIN STREET</AddressLine1Txt>
          <CityNm>BURLINGTON</CityNm>
          <StateAbbreviationCd>VT</StateAbbreviationCd>
          <ZIPCd>05401</ZIPCd>
        </USAddress>
        <GrantDt>2018-05-17</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>FOR DEVELOPING INTEGRATED CLINICAL ASSESSMENT AND DATA ANALYTICS PLATFORMS AND OTHER DERIVATIVE PRODUCTS THAT TRANSFORM POINT-OF-CARE MEDICINE BY PUTTING VALIDATED CLINICAL ASSESSMENT CAPABILITY AND INCREASED HEALTHCARE KNOWLEDGE INTO THE HANDS OF CLINICALLY UNTRAINED HEALTHCARE PROFESSIONALS AND FAMILIES THEREBY LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 2/1/2024, 6/4/2024, 10/14/2024, 3/31/2025, 5/28/2025</DatesOfReportsByGranteeTxt>
        <VerificationDt>2019-02-11</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH THINKMD, INC. MANAGEMENT ON A REGULAR BASIS, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
    </ExpenditureResponsibilityStmt>
    <InvestmentsCorpBondsSchedule documentId="RetDoc2044400001">
      <InvestmentsCorporateBondsGrp>
        <BondNm>FIXED INCOME</BondNm>
        <EOYBookValueAmt>17658588</EOYBookValueAmt>
        <EOYFMVAmt>17658588</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
    </InvestmentsCorpBondsSchedule>
    <InvestmentsCorpStockSchedule documentId="RetDoc2018900001">
      <InvestmentsCorporateStockGrp>
        <StockNm>DOMESTIC EQUITIES</StockNm>
        <EOYBookValueAmt>34981743</EOYBookValueAmt>
        <EOYFMVAmt>34981743</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOREIGN SECURITIES</StockNm>
        <EOYBookValueAmt>12360960</EOYBookValueAmt>
        <EOYFMVAmt>12360960</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
    </InvestmentsCorpStockSchedule>
    <InvestmentsOtherSchedule2 documentId="RetDoc2018100001">
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>REAL ESTATE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6061378</BookValueAmt>
        <EOYFMVAmt>6061378</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ALTERNATIVE INVESTMENTS</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17615779</BookValueAmt>
        <EOYFMVAmt>17615779</EOYFMVAmt>
      </InvestmentsOtherGrp>
    </InvestmentsOtherSchedule2>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>LEGAL EXPENSES</CategoryTxt>
        <LegalFeesAmt>20204</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>20204</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherAssetsSchedule documentId="RetDoc2046600001">
      <OtherAssetsScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENTS</Desc>
        <BOYBookValueAmt>4006057</BOYBookValueAmt>
        <EOYBookValueAmt>4579307</EOYBookValueAmt>
        <EOYFMVAmt>4579307</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
    </OtherAssetsSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>FILING FEES</Desc>
        <RevenueAndExpensesPerBooksAmt>539</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>539</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>MISCELLANEOUS EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>6623</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>6623</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>HRIA ADMINISTRATIVE COSTS</Desc>
        <RevenueAndExpensesPerBooksAmt>244367</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>244367</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENT ADMINISTRATIVE COSTS</Desc>
        <RevenueAndExpensesPerBooksAmt>23964</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>23964</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>MARKETING</Desc>
        <RevenueAndExpensesPerBooksAmt>4722</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>4722</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>HONORARIA</Desc>
        <RevenueAndExpensesPerBooksAmt>17807</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>17807</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>TUFTS ADMINISTRATIVE EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>62075</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>62075</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherIncomeSchedule2 documentId="RetDoc2001500001">
      <OtherIncomeDetail>
        <Desc>INCOME FROM ALTERNATIVE INVESTMENTS</Desc>
        <RevenueAndExpensesPerBooksAmt>181544</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>181544</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>181544</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>RETURNED GRANTS</Desc>
        <RevenueAndExpensesPerBooksAmt>26256</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>26256</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER INVESTMENT INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>882</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>882</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
    </OtherIncomeSchedule2>
    <OtherIncreasesSchedule documentId="RetDoc2049700001">
      <OtherIncreasesDetail>
        <Desc>UNREALIZED GAIN</Desc>
        <Amt>3997991</Amt>
      </OtherIncreasesDetail>
    </OtherIncreasesSchedule>
    <OtherProfessionalFeesSchedule documentId="RetDoc2002300001">
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT FEES - US TRUST</CategoryTxt>
        <Amt>37630</Amt>
        <NetInvestmentIncomeAmt>18815</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>18815</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT CONSULTING</CategoryTxt>
        <Amt>78750</Amt>
        <NetInvestmentIncomeAmt>78750</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
    </OtherProfessionalFeesSchedule>
    <TaxesSchedule documentId="RetDoc2002500001">
      <TaxesDetail>
        <CategoryTxt>FEDERAL EXCISE TAXES FOR 2024</CategoryTxt>
        <Amt>105000</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>MA FORM PC FILING FEE</CategoryTxt>
        <Amt>500</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>500</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FOREIGN TAXES</CategoryTxt>
        <Amt>40752</Amt>
        <NetInvestmentIncomeAmt>40752</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
    </TaxesSchedule>
  </ReturnData>
</Return>